Researchers at the McGovern and Broad Institutes have developed a bacterial "nanosyringe" that can inject large proteins into specific cells in the body, which could lead to safer and more effective treatments for a variety of conditions, including cancer, reports Michael Le Page for New Scientist. “The fact that this can load a diversity of different payloads of different sizes makes it unique amongst protein delivery devices,” says graduate student Joseph Kreitz.
Ingrid Wickelgren at Scientific American highlights a new study from researchers at the McGovern and Broad Institutes, in which they used a bacterial ‘nanosyringe’ to inject large proteins into human cells. “The syringe technology also holds promise for treating cancer because it can be engineered to attach to receptors on certain cancer cells,” writes Wickelgren.
Al Jazeera reporter Somesh Jha highlights the work of research associate Georgios Petropoulos, who is examining the ways in which artificial intelligence can impact jobs. “His work has shown that in past industrial revolutions too, the displacement of jobs might have dominated in the short run,” writes Jha, “but in the long term, when the markets adapt to the automation shock, increased productivity actually sets the stage for more employment opportunities.”
Prof. Aleksander Mądry’s testimony before a House subcommittee was highlighted by Politico fellow Mohar Chatterjee in a recent newsletter exploring how large tech companies are dominating how generative AI technologies are developed and utilized. During his testimony, Mądry emphasized that “very few players will be able to compete, given the highly specialized skills and enormous capital investments the building of such systems requires.”
Researchers at MIT have quantified the shift toward the artificial intelligence industry and how it has impacted academia, reports Madhumita Murgia for Financial Times. “The MIT research found that almost 70 percent of AI PhDs went to work for companies in 2020, compared to 21 per cent in 2004,” writes Murgia.
Using an artificial intelligence system, researchers at MIT and elsewhere have developed a new Covid-19 vaccine that could be effective against current and future strains, reports Gwen Egan for Boston.com. “The vaccine differs from others currently on the market due to the portion of the virus being targeted,” writes Egan.
Wired reporter Will Knight spotlights a new working paper by graduate students Shakked Noy and Whitney Zhang examining the impact of providing office workers access to ChatGPT for use in a series of office tasks. The researchers found “people with access to the chatbot were able to complete the assigned tasks in 17 minutes, compared to an average 27 minutes for those without the bot, and that the quality of their work improved significantly,” writes Knight.
Boston Globe reporter Hiawatha Bray writes that MIT researchers have used an AI system to identify a potential new Covid-19 vaccine that may be effective against both current and future variants of the virus. “The new vaccine targets a portion of the COVID virus that is much less prone to evolve,” writes Bray. “That could potentially make it effective against many different versions of the virus, eliminating the need for routine booster shots.”
MIT researchers have developed a new approach to vaccines that uses “a machine learning twist [that] could put an end to boosters and seasonal variant shots,” reports Devin Coldewey for TechCrunch.
Researchers at MIT developed a system that uses artificial intelligence to help predict future risk of developing breast cancer, reports Poppy Harlow for CNN. What this work does “is identifies risk. It can tell a woman that you’re at high risk for developing breast cancer before you develop breast cancer,” says Larry Norton, medical director of the Lauder Breast Center at the Memorial Sloan Kettering Cancer Center.
Writing for Fast Company, Visiting Scientist Priya Donti examines how “scientists are increasingly looking to AI to help us predict the weather, and some of the most promising approaches come from blending AI with existing scientific knowledge.” Donti notes that a “combination of innovative technology and human wisdom is the best way to harness AI to help us tackle the challenges of the future, especially climate change.”
Joy Buolamwini PhD ’22 has been named one of Diverse: Issues in Higher Education’s Top Women for 2023 for her work in developing “more equitable and accountable technology.” Buolamwini “uncovered racial and gender bias in AI services from high profile companies such as Microsoft, IBM and Amazon. Now a sought-after international speaker, Buolamwini continues to advocate for algorithmic justice,” writes Diverse: Issues in Higher Education.
Dean Daniel Huttenlocher joins CNBC’s “Squawk on the Street” to discuss the current state of AI and how generative AI advances could impact our future. “These recent advances in generative AI technology really do represent a completely different capability in computing than anything we have experienced,” says Huttenlocher. “This is the first tech that can create humanlike expression.”
Writing for The Wall Street Journal, Dean Daniel Huttenlocher, former Secretary of State Henry Kissinger and former Google CEO Eric Schmidt explore how generative artificial intelligence “presents a philosophical and practical challenge on a scale not experienced since the beginning of the Enlightenment.” Huttenlocher, Kissinger and Schmidt make the case that “parameters for AI’s responsible use need to be established, with variation based on the type of technology and the context of deployment.”
Graduate student Ziv Epstein speaks with Vice reporter Rachel Cheung about the legal implications of the development and use of AI tools being used to create art. “We need more both technical and social research, understanding how these things work, how people feel about them, and then we can make those decisions based on good science,” Epstein said. “Because right now, we’re just really at the brink of the beginning.”